PriceTargets.com logo

Tricida - TCDA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 01/23/2023 05:00 PM ET
+0 (0.00%)
Get New Tricida Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCDA

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Tricida in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for TCDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Tricida. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/25/2022JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
10/25/2022Needham & Company LLCDowngradeBuy ➝ HoldLow
10/24/2022CowenDowngradeMarket PerformN/A
10/24/2022CowenDowngradeOutperform ➝ Market PerformN/A
5/24/2022The Goldman Sachs GroupLower TargetBuy$22.00 ➝ $16.00Low
4/12/2022The Goldman Sachs GroupInitiated CoverageBuy$25.00Low
3/30/2022Needham & Company LLCReiterated RatingBuy$20.00 ➝ $18.00Medium
11/16/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$7.00High
8/10/2021Needham & Company LLCInitiated CoverageBuy$20.00High
9/29/2020JPMorgan Chase & Co.Initiated CoverageUnderweight$8.00High
8/25/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$25.00 ➝ $10.00High
8/24/2020Needham & Company LLCReiterated RatingBuy$44.00 ➝ $20.00High
8/9/2020CowenReiterated RatingBuy$40.00Low
8/6/2020Needham & Company LLCLower TargetBuy$50.00 ➝ $44.00Medium
7/16/2020Needham & Company LLCReiterated RatingBuy$50.00High
10/15/2019CowenSet TargetBuy$50.00Low
8/12/2019Needham & Company LLCSet TargetBuy$50.00Medium
8/8/2019CowenReiterated RatingBuy$50.00High
6/26/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$48.00High
6/25/2019CowenReiterated RatingBuy$50.00Low
5/24/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$50.00Medium
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Tricida logo
Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.13
Low: $0.11
High: $0.19

52 Week Range

Now: N/A

Volume

31,125,300 shs

Average Volume

17,618,414 shs

Market Capitalization

$6.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Tricida?

The following sell-side analysts have issued reports on Tricida in the last twelve months:
View the latest analyst ratings for TCDA.

What is the current price target for Tricida?

0 Wall Street analysts have set twelve-month price targets for Tricida in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Tricida in the next year.
View the latest price targets for TCDA.

What is the current consensus analyst rating for Tricida?

Tricida currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TCDA.

What other companies compete with Tricida?

Other companies that are similar to Tricida include Avenue Therapeutics, Xenetic Biosciences, Vaccinex, Hoth Therapeutics and Ayala Pharmaceuticals. Learn More about companies similar to Tricida.

How do I contact Tricida's investor relations team?

Tricida's physical mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (415) 429-7800 and its investor relations email address is [email protected]. The official website for Tricida is www.tricida.com. Learn More about contacing Tricida investor relations.